British Columbia says it will save more than $96 million in its prescription drug program by expanding the use of so-called biosimilar drugs to treat diabetes, arthritis and Crohn's disease.
The Ontario government will announce Monday that it intends to join British Columbia's proposed class action lawsuit against dozens of opioid manufacturers.
